News

MRI can help differentiate multiple sclerosis with cavitary lesions from VWMD


 

FROM EUROPEAN JOURNAL OF NEUROLOGY

References

The morphology of brain lesions can provide strong clues for differentiating patients with multiple sclerosis (MS) with cavitary lesions from patients with vanishing white matter disease (VWMD), suggests a cross-sectional study conducted in France.

The study comprised 14 patients with MS with cavitary lesions and 14 patients with VWMD. Two neuroradiologists reviewed brain MRI scans for the patients.

HUNG KUO CHUN/Thinkstock

All of the patients with MS had ovoid lesions perpendicular to the lateral ventricles and half of such patients had isolated juxtacortical lesions. None of the VWMD patients had either of those types of lesions.

Another of the neuroradiologists’ findings was that 58% of the VWMD patients had symmetrical hyperintensities in the infratentorial region of the brain, mainly involving the middle cerebellar peduncle and cerebellar white matter, while symmetrical hyperintensities were absent from that part of the brain in MS patients.

Other statistically significant differences between the brains of the two groups were the percentages of each group that had hyperintensities located in the midbrain and thalamus. Both were found in more than 70% of MS patients. In contrast, midbrain and thalamus hyperintensities were found in 29% and 7% of the VWMD patients, respectively.

While it is difficult to distinguish MS with cavitary lesions from VWMD, this study “clearly shows some MRI characteristics that seems to be specific and thus help to differentiate these two disorders,” wrote Xavier Ayrignac and his colleagues.

Read the study in the European Journal of Neurology (doi: 10.111/ene.12931).

klennon@frontlinemedcom.com

Recommended Reading

Relapses and MRI Activity Predict MS Treatment Response
MDedge Neurology
NEDA-4 May Predict MS Outcomes Better Than NEDA-3
MDedge Neurology
Study suggests radiologically isolated disease is part of MS spectrum
MDedge Neurology
Extended Dosing Improves Safety of Natalizumab in MS Treatment
MDedge Neurology
Polyunsaturated Fatty Acids May Reduce Risk of MS
MDedge Neurology
Evidence points to early brain cell death as catalyst for MS inflammation, demyelination
MDedge Neurology
Radiologically Isolated Disease Is Part of the MS Spectrum
MDedge Neurology
Amiselimod May Provide Benefits for Patients With Relapsing-Remitting MS
MDedge Neurology
Neuromyelitis Optica Spectrum Disorder Presents Diagnostic and Treatment Challenges
MDedge Neurology
T-cell biomarker not viable for detecting PML risk with natalizumab
MDedge Neurology